Abstract Number: PB0730
Meeting: ISTH 2022 Congress
Background: Cancer growth develops a subclinical hypercoagulable state and hypercoagulability is also a key contributor in cancer progression beyond cancer-associated thrombosis. Increasing evidence shows that coagulation proteins have multiple functions in tumor progression and metastasis, however the role of natural anticoagulants in cancer remains barely unexplored. Activated protein C (APC) displays anticoagulant and cytoprotective functions and its dysregulation may prompt cancer growth.
Aims: To ascertain whether circulating APC levels are dysregulated in cancer patients.
Methods: We obtained heparinized plasma from 88 cancer patients (45 bladder, 15 sarcoma, 9 renal and 19 prostate) and 14 controls, namely patients with a cancer suspicion anatomopathologically discarded. Circulating APC was quantified with an in-house sandwich ELISA, based on the interaction between APC and its main natural inhibitor PCI. Briefly, heparin forces APC:PCI complexation and these complexes are measured using an anti-PC primary antibody and an anti-PCI secondary antibody. Differences in circulating APC between groups was assessed with a Mann-Whitney test using GraphPad (v.8.0.1).
Results: Compared to controls, cancer patients showed a 16% reduction in circulating APC concentration (P=0.0210) (Figure 1). Attending to the different cancer types, bladder cancer patients showed a 23% APC decrease (P=0.0038) and sarcoma patients showed a 14% decrease (P=0.0116), whereas renal and prostate cancer patients did not show a significant decrease.
Conclusion(s): Circulating APC levels are significantly decreased in cancer patients. Differences among cancer types may be due to differential contribution of APC in tumorigenesis or by the regulation driven by cancer cells on APC levels. The reduction in circulating APC may further enhance hypercoagulability in cancer patients while reducing its cytoprotective functions, thus contributing to tumorigenesis. ISCIII-FEDER (PI17/00495, PI20/00075, FI21/00171), GVA (ACIF/2017/138) and SETH.
To cite this abstract in AMA style:Oto J, Herranz R, Plana E, Cana F, Amaya J, Vera-Donoso C, Martínez-Sarmiento M, Bonanad S, Medina P. Circulating activated protein C levels are reduced in cancer patients, a novel contribution to tumorigenesis? [abstract]. https://abstracts.isth.org/abstract/circulating-activated-protein-c-levels-are-reduced-in-cancer-patients-a-novel-contribution-to-tumorigenesis/. Accessed September 27, 2022.
« Back to ISTH 2022 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/circulating-activated-protein-c-levels-are-reduced-in-cancer-patients-a-novel-contribution-to-tumorigenesis/